The Value of Radioligand Therapy in Community Oncology: World-Class Care Close to Home

As a physicist working in cancer care, I see both the technical and human sides of treatment. I see the science, planning, safety checks, and coordination required to deliver advanced therapies well. I also see patients and families trying to receive the best care possible without leaving behind their jobs, homes, and support systems.

After 13 years in nuclear medicine and 6 years in medical physics, I have seen how meaningful radioligand therapy (RLT) can be for both patients and cancer programs. I have also seen that strong programs are built on interdisciplinary collaboration, with clear communication among oncology, imaging, pharmacy, nursing, radiation safety, operations, and physics. When that foundation is in place, RLT can become a dependable part of community cancer care.

That is why RLT matters so much in community oncology. At Highlands Oncology Group, we believe patients should not have to travel to a distant academic center to receive exceptional cancer care. Our goal is to bring world-class oncology services to northwest Arkansas and the surrounding region while keeping care personal, accessible, and close to home. In areas where many patients live outside large metropolitan centers, that approach offers more than convenience; it expands access to advanced treatment for people who might otherwise face delays, travel burdens, or the decision to forego care.

RLT is one of the clearest examples of that mission in action. RLT is a targeted treatment that pairs highly specific imaging biology with a therapeutic radioactive agent that binds to cancer cells more precisely than many conventional approaches. Whether the target is a somatostatin receptor, prostate-specific membrane antigen expression, or another biologic pathway, the principle is the same: identify the right patient, confirm the target, and deliver therapy with intention. That blend of imaging, biology, and treatment is what makes RLT one of the most practical forms of precision medicine in oncology.

For patients, the value is not only in the science but also in the setting. When these therapies are available in a trusted community oncology practice, patients can remain connected to the care team they already know. They can receive highly specialized treatment while staying near family, work, and familiar routines. Cancer care is hard enough without adding long travel days, overnight stays, fragmented follow-up, and the stress of navigating an unfamiliar system. Receiving advanced therapy close to home can improve access, continuity, confidence, and the overall treatment experience.

From the practice side, RLT strengthens the entire cancer program. It requires coordination among medical oncology, radiation oncology, nuclear medicine, imaging, pharmacy, nursing, research, physics, and operations. It does not succeed by accident; it succeeds when a practice invests in workflows, staff training, regulatory discipline, patient education, and treatment oversight. That level of coordination raises the organization’s standards and benefits patients.

The payer perspective also matters. RLT should not be viewed only as a high-cost drug or a single treatment day. It is part of a care model that includes diagnostic imaging, thoughtful patient selection, safe treatment delivery, toxicity monitoring, and structured follow-up. When payers support access in the community setting, they support a model that can reduce disruption, improve coordination, and remove practical barriers that often delay care.

Operationally, offering RLT in community oncology takes planning and discipline. A practice must have strong workflows for imaging, scheduling, radiation safety, staff education, regulatory compliance, patient counseling, and follow-up. In some settings, it also requires readiness for dosimetry, waste handling, documentation, and cross-department scheduling. These are real demands, but they are worthwhile investments because they allow a community practice to deliver advanced, personalized cancer care with both technical rigor and local accountability.

Over the next 5 years, I believe the road map for RLT in community oncology will center on thoughtful growth. It begins with strong infrastructure, reliable protocols, and a well-trained team. From there, practices can expand referral pathways, improve efficiency, and identify appropriate patients earlier. As theranostics continues to mature, more community programs will integrate additional radiopharmaceutical therapies into routine practice. The organizations that do this well will combine innovation with compassion and technical excellence with community responsibility.

From where I sit, the value of RLT is clear. It is not just about offering the newest treatment. It is about building a system capable of delivering the right treatment to the right patient at the right time without asking that patient to leave their community to receive it.

That is the real promise of community oncology—not smaller care, but smarter, more accessible, and more human care. That is why RLT matters.

Author Information

J. Tyler Middlebrooks, MS, RSO, CNMT, NMTCB(RS), RT(N)(CT), LBBH, is the principal radiopharmaceutical physicist and radiation safety officer at Highlands Oncology, based in Fayetteville, Arkansas.